Carole Miller, MD, discusses notable factors which correlated with survival for patients with polycythemia vera in the REVEAL study.
Carole Miller, MD, director of the Cancer Institute at Ascension Saint Agnes, discusses notable factors which correlated with survival for patients with polycythemia vera (PV) in the REVEAL study (NCT02252159).
While the overall survival for patients with PV is estimated to be 20 years, uncertainty remains regarding what factors that impact mortality within this patient population. To address this clinical question, an analysis was designed within the phase 4 study to examine mortality and causes of death in patients with PV.
Patients aged 18 years or older with a life expectancy below 6 months were enrolled, including those who had a history of or an active plan to proceed to allogeneic hematopoietic stem cell transplant within 3 months, and those who had a splenectomy.
Transcription:
0:08 | Significantly more patients who died in the study were characterized as high-risk at diagnosis. That makes sense, but it was primarily due to age. There wasn't a clear difference between the patients who died and were alive at the time about whether they had thromboembolic events prior to enrollment. Patients who died had higher symptom scores at all the different time points. Patients were screened about every 3 months.
0:48 | When you look at all points, the patients who died had worse symptoms than the patients who lived, but I guess that is expected. The patients who died in the 6 to 9 months with a longer follow up had significantly worse quality of life symptoms than the patients who remained alive during the course of the study. The things that pushed the increase in symptoms were generally fatigue, early satiety, difficulty concentrating, and unintentional weight loss. These were specific complaints related to polycythemia vera.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More